What the research found

This is a first-person account rather than a research study, so the findings are observational and limited to one individual's experience across three testosterone delivery methods. The author trialled testosterone cream (minimal effect), pellets (strong initial response followed by cyclical decline in symptom relief around week 10), and injectables (sustained consistency over 18 months with twice-weekly dosing). The pellet cycle pattern was particularly notable: symptom improvement peaked shortly after insertion, then deteriorated predictably before the next scheduled insertion, creating what the author describes as a "roller coaster" effect—especially when combined with estrogen pellets on the same insertion schedule.

The shift to injectable testosterone allowed for dose titration based on both symptoms and lab results, checked roughly every 12 weeks after initial stabilisation. The author also notes personal inconsistency with topical formulations (cream and patch), attributing this to inter-individual variation in skin absorption and other absorption variables rather than a blanket failure of topicals as a class.

Why it matters for you

If you're tracking testosterone via biomarkers and symptom logs in MyKine, this account illustrates why your delivery method choice directly affects how useful those logs become. Pellet users should expect meaningful symptom variation across the dosing cycle—energy, libido, training recovery, and cognitive clarity may all track predictably with insertion timing rather than representing true hormonal insufficiency. This pattern can be invisible without month-by-month symptom tracking.

For those on injectables or considering the switch, the emphasis on frequent lab checks (especially during titration) and symptom-guided dosing is relevant to your protocol design. The author's move from weekly to twice-weekly injections to smooth out fluctuations suggests that dosing frequency, not just total dose, influences perceived consistency—something you might experiment with if you're optimising for stable energy and recovery metrics.

If topical testosterone isn't delivering the biomarker shifts or symptom improvements you expected, absorption variability is a legitimate explanation; it doesn't mean you're a non-responder to testosterone itself.

Caveats

  • N of 1: This is one person's subjective experience and biology; individual absorption, skin physiology, and response will vary significantly.
  • No objective measurements: The reported improvements (libido, brain fog, recovery) are subjective; no metabolic rate, body composition, or strength data are provided.
  • Confounding variables: Training intensity, sleep, stress, and diet are not controlled and likely changed across the three phases.
  • Selection bias in clinic choice: The author's experience with pellets may reflect that particular clinic's insertion protocol or product formulation, not all pellet testosterone.
  • No side effect tracking: Long-term safety or adverse event data (lipids, haematocrit, etc.) are not discussed.